Comparison of four commercial viral load techniques in an area of non-B HIV-1 subtypes circulation

Journal of Virological Methods

Volumn 222, Issue , 2015, Pages 122-131

  Ndiaye, Ousseynou ^a   Diop Ndiaye, Halimatou ^a   Ouedraogo, Abdou Salam ^b   Fall Malick, Fatim Zahra ^a   Sow Sall, Amina ^a   Thiam, Moussa ^a   Diouara, Abou Abadallah Malick ^a   Ndour, Cheikh Tidiane ^a   Gaye Diallo, Aïssatou ^a   Mboup, Souleymane ^a   Toure Kane, Coumba ^a   Khady, Kebe ^c   Diouf, Nafissatou Leye ^c   Diouf, Ndèye Aminata Diaw ^c   Diallo, Sada ^c   Gueye, Sokhna Bousso ^c   Gueye, Diabou ^c   Fall, Bineta Seck ^d   Maynart, Maryvonne ^d   Gaye, Nogaye ^d   Sall, Caroline Desclaux ^d   more..

^a UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^b UNIVERSITÉ DE OUAGADOUGOU   (Burkina Faso)

^c Centre Hospitalier Universitaire Aristide Le Dantec de Dakar   (Senegal)

^d Centre Regional de Recherche et de Formation sur la Prise en chargeclinique   (Senegal)

Author keywords

Comparison; HIV 1; Viral load

Indexed keywords

GAG PROTEIN; POL PROTEIN; VIRUS RNA;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEVICE COMPARISON; GAG GENE; GENE SEQUENCE; GENOTYPE; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS 1; LIMIT OF QUANTITATION; MEASUREMENT REPEATABILITY; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS LOAD; COMPARATIVE STUDY; DNA SEQUENCE; EVALUATION STUDY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; PROCEDURES; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD;

EID: 84932626967     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2015.06.002     Document Type: Article

References (26)

1. Bekker L.G., Myer L., Orrell C., Lawn S., Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S. Afr. Med. J. 2006, 96:315-320.
2. Bourlet T., Signori-Schmuck A., Roche L., Icard V., Saoudin H., Trabaud M.A., Tardy J.C., Morand P., Pozzetto B., Ecochard R., André P. HIV-1 load comparison using four commercial real-time assays. J. Clin. Microbiol. 2011, 49:292-297.
3. Braun P., Ehret R., Wiesmann F., Zabbai F., Knickmann M., Kuhn R., Thamm S., Warnat G., Knechten H. Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine. Clin. Chem. Lab. Med. 2007, 45:93-99.
4. Church D., Gregson D., Lloyd T., Klein M., Beckthold B., Laupland K., Gill M.J. Comparison of the RealTime HIV-1, COBAS TaqMan 48 v1.0, Easy Q v1.2, and Versant v3.0 assays for determination of HIV-1 viral loads in a cohort of Canadian patients with diverse HIV subtype infections. J. Clin. Microbiol. 2011, 49:118-124.
5. Conseil National de Lutte contre le Sida Rapport de situation sur la riposte nationale de l'épidémie de VIH/SIDA Sénégal: 2010-2011 2011, http://www.unaids.org/sites/default/files/country/documents//SEN_narrative_report_2014.pdf.
6. Da Silva D., Van Wesenbeeck L., Breilh D., Reigadas S., Anies G., Van Baelen K., Morlat P., Neau D., Dupon M., Wittkop L., Fleury H., Masquelier B. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens. J. Antimicrob. Chemother. 2010, 65:1262-1269.
7. de Baar M.P., van Dooren M.W., de Rooij E., Bakker M., van Gemen B., Goudsmit J., de Ronde A. Single rapid real-time monitored isothermal RNA amplification assay for quantitation of human immunodeficiency virus type 1 isolates from groups M, N, and O. J. Clin. Microbiol. 2001, 39:1378-1384.
8. Drexler J.F., de Souza Luna L.K., Pedroso C., Pedral-Sampaio D.B., Queiroz A.T., Brites C., Netto E.M., Drosten C. Rates of and reasons for failure of commercial human immunodeficiency virus type 1 viral load assays in Brazil. J. Clin. Microbiol. 2007, 45:2061-2203.
9. Geelen S., Lange J., Borleffs J., Wolfs T., Weersink A., Schuurman R. Failure to detect a non-B HIV-1 subtype by the HIV-1 Amplicor monitor test, version 1.5: a case of unexpected vertical transmission. AIDS 2003, 17:781-782.
10. Gomes P., Carvalho A.P., Diogo I., Gonçalves F., Costa I., Cabanas J., Camacho R.J. Comparison of the NucliSENS EasyQ HIV-1 v2.0 with Abbott m2000rt RealTime HIV-1 assay for plasma RNA quantitation in different HIV-1 subtypes. J. Virol. Methods 2013, 193:18-22.
11. Gouy M., Guindon S., Gascuel O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol. Biol. Evol. 2010, 27:221-224.
12. Hamel D.J., Sankalé J.-L., Eisen G., Meloni S.T., Mullins C., Gueye-Ndiaye A., Mboup S., Kanki P.J. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res. Hum. Retrovir. 2007, 23:1189-1196.
13. Hirsch M.S., Günthard H.F., Schapiro J.M., Brun-Vézinet F., Clotet B., Hammer S.M., Johnson V.A., Kuritzkes D.R., Mellors J.W., Pillay D., Yeni P.G., Jacobsen D.M., Richman D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Top. HIV Med. 2008, 16:266-285. International AIDS Society-USA.
14. Holguín A., López M., Molinero M., Soriano V. Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. J. Clin. Microbiol. 2008, 46:2918-2923.
15. Korenromp E.L., Williams B.G., Schmid G.P., Dye C. Clinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection - a quantitative review. PLoS ONE 2009, 4:e5950.
16. Laurent C., Ngom Gueye N.F., Ndour C.T., Gueye P.M., Diouf M., Diakhaté N., Touré Kane N.C., Lanièce I., Ndir A., Vergne L., Ndoye I., Mboup S., Sow P.S., Delaporte E. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J. Acquir. Immune Defic. Syndr. 2005, 38:14-17. ANRS 1215/1290 Study Group.
17. Ndiaye H.D., Tchiakpe E., Vidal N., Ndiaye O., Diop A.K., Peeters M., Mboup S., Toure-Kane C. HIV type 1 subtype C remains the predominant subtype in men having sex with men in Senegal. AIDS Res. Hum. Retrovir. 2013, 29:1265-1272.
18. Rouet F., Foulongne V., Viljoen J., Steegen K., Becquart P., Valéa D., Danaviah S., Segondy M., Verhofstede C., Van de Perre P. Comparison of the generic HIV viral load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J. Virol. Methods 2010, 163:253-257. WHO/ANRS 1289 Kesho Bora Study Group.
19. Scott L.E., Noble L.D., Moloi J., Erasmus L., Venter W.D., Stevens W. Evaluation of the Abbott m2000 RealTime human immunodeficiency virus type 1 (HIV-1) assay for HIV load monitoring in South Africa compared to the Roche Cobas AmpliPrep-Cobas Amplicor, Roche Cobas AmpliPrep-Cobas TaqMan HIV-1, and BioMerieux NucliSENS EasyQ HIV-1 assays. J. Clin. Microbiol. 2009, 47:2209-2217.
20. Sollis K.A., Smit P.W., Fiscus S., Ford N., Vitoria M., Essajee S., Barnett D., Cheng B., Crowe S.M., Denny T., Landay A., Stevens W., Habiyambere V., Perrins J., Peeling R.W. Systematic review of the performance of HIV viral load technologies on plasma samples. PLOS ONE 2014, 9:e85869.
21. Swanson P., de Mendoza C., Joshi Y., Golden A., Hodinka R.L., Soriano V., Devare S.G., Hackett J. Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. J. Clin. Microbiol. 2005, 43:3860-3868.
22. Thiam M., Diop-Ndiaye H., Diouf A.D., Vidal N., Ndiaye O., Ndiaye I., Ngom-Gueye N.F., Diallo S., Diongue O.D., Camara M., Seck A., Mboup S., Toure-Kane C. HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. J. Clin. Microbiol. 2013, 51:578-584.
23. Toure-Kane C., Montavon C., Faye M.A., Gueye P.M., Sow P.S., et al. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res. Hum. Retrovir. 2000, 16:603-609.
24. Wang Y., Song A., Xu S., Li X., Chong H., Zhao C., Nie J., Zhang C. Impact of HIV-1 genetic diversity in China on the measurement of viral load. J. Med. Virol. 2008, 80:1-8.
25. World Health Organization Guidelines. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach 2013, 272 pp., http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
26. Yilmaz G. Diagnosis of HIV infection and laboratory monitoring of its therapy. J. Clin. Virol. 2001, 21:187-196.